Thoroughbred Financial Services LLC Sells 1,111 Shares of Danaher Co. (NYSE:DHR)

Thoroughbred Financial Services LLC cut its position in Danaher Co. (NYSE:DHR) by 56.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 873 shares of the conglomerate’s stock after selling 1,111 shares during the quarter. Thoroughbred Financial Services LLC’s holdings in Danaher were worth $218,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in DHR. Wellington Management Group LLP increased its stake in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after purchasing an additional 2,998,161 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after buying an additional 1,619,586 shares during the last quarter. Capital International Investors boosted its stake in shares of Danaher by 9.1% during the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after acquiring an additional 1,334,781 shares during the period. Norges Bank acquired a new position in shares of Danaher during the 4th quarter worth approximately $1,752,382,000. Finally, Franklin Resources Inc. raised its stake in Danaher by 6.4% in the 4th quarter. Franklin Resources Inc. now owns 6,620,170 shares of the conglomerate’s stock valued at $1,531,510,000 after acquiring an additional 395,498 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Evercore ISI dropped their price objective on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. TD Cowen raised their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Jefferies Financial Group began coverage on Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price on the stock. Barclays lifted their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Finally, StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $268.67.

Insider Activity

In related news, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the transaction, the chief executive officer now owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the transaction, the chief executive officer now owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares in the company, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Insiders sold a total of 148,783 shares of company stock valued at $37,536,717 over the last three months. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Up 1.0 %

DHR traded up $2.46 during midday trading on Tuesday, reaching $248.69. 741,703 shares of the company were exchanged, compared to its average volume of 2,843,650. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The company’s fifty day moving average price is $254.99 and its 200 day moving average price is $247.73. The company has a market cap of $184.20 billion, a price-to-earnings ratio of 41.73, a price-to-earnings-growth ratio of 3.77 and a beta of 0.84. Danaher Co. has a one year low of $182.09 and a one year high of $269.11.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s quarterly revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.36 earnings per share. As a group, analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio is presently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.